ASSTON PHARMACEUTICALS LIMITED is a Pharmaceuticals & Biotechnology company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
| ₹ crore · consolidated | FY26 |
|---|---|
| Revenue | 25 |
| EBITDA (ex other income) | (1) |
| margin % | (2.2) |
| Owners' profit | 4 |
| EPS, as reported (₹) | 4.92 |
| ROE % · ROCE % | 9.9 · 12.3 |
| Debt / equity (x) | 0.13 |
| Cash from operations | (10) |
| Capex | (10) |
| ₹ crore | Q2 FY26 | Q4 FY26 |
|---|---|---|
| Revenue | 15 | 10 |
| Profit before tax | 0 | 1 |
| Net profit | 0 | 0 |
| EPS (₹) | 0.05 | 1.14 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 | 25.2 |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 7 Sept 2026 · Asston Pharmaceuticals files 7th Annual Report for FY 2025-26 | compliance | low | — | — |
| 7 Sept 2026 · 7th AGM on Sep 29; auditor re-appointment and director pay hikes on agenda | board shareholder meetings | low | — | — |
| 5 Sept 2026 · Asston Pharma allots 24.1 lakh shares at Rs 115 via preferential issue | fund raising | high | — | — |
| 5 Sept 2026 · Asston Pharma allots 24.10 lakh shares at Rs 115 via preferential route | fund raising | high | — | — |
| 4 Sept 2026 · Board approves auditor appointments, director pay hike, sets AGM cut-off date Sept 22 | board shareholder meetings | low | — | — |
| 4 Sept 2026 · 7th AGM on Sept 29, 2026; board OKs auditor changes, director pay rise | board shareholder meetings | low | — | — |
| 4 Sept 2026 · Board OKs auditor changes, MD reappointment, pay hike; AGM on Sep 29 | board shareholder meetings | medium | — | — |
| 4 Sept 2026 · Board approves auditor appointments, MD re-appointment and AGM on 29 Sep | management changes | medium | — | — |
| 4 Sept 2026 · Board approves auditor appointments, MD re-appointment, AGM on Sept 29 | management changes | medium | — | — |
| 4 Sept 2026 · Board approves new auditors, director pay hikes, 7th AGM on Sept 29 | board shareholder meetings | low | — | — |
| Where a broker report shows | This document shows | Why |
|---|
| 96,656 |
| 26.3 |
| 2.55 |
| 13.4 |
| 9.2 |
| 12.6 |
| 6.3 |
| 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 91.6 | 28.9 | 151 of 169 | 11% |
| P/B | 2.4 | 3.3 | 62 of 163 | 62% |
| ROCE | 10.8 | 10.8 | 91 of 183 | 51% |
| ROE | 9.9 | 10.4 | 87 of 171 | 49% |
| Debt / Equity | 0.1 | 0.1 | 84 of 171 | 51% |
| EBITDA margin | 18.2 | 17.5 | 78 of 165 | 53% |
| Market cap | 93 | 839 | 138 of 182 | 24% |
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
